ライフサイエンスコーパス: vascular dementia

1 ing cerebrovascular disease, and 44 cases of vascular dementia).

2 nt dementia (n = 532 AD and n = 154 mixed or vascular dementia).

3 hippocampus and corpus callosum in rats with vascular dementia.

4 proval in most of the world for treatment of vascular dementia.

5 se inhibitors and memantine in patients with vascular dementia.

6 f cholinesterase inhibitors and memantine in vascular dementia.

7 gnificance in patients with mild to moderate vascular dementia.

8 cutive impairment as a diagnostic marker for vascular dementia.

9 ight serve as a useful diagnostic marker for vascular dementia.

10 milder stages of Alzheimer's disease or for vascular dementia.

11 ern was observed for Alzheimer's disease and vascular dementia.

12 d risk of dementia, Alzheimer's disease, and vascular dementia.

13 hard to classify, and one was diagnosed with vascular dementia.

14 size of neurons in CA1 in AD versus ischemic vascular dementia.

15 ps of alcohol use with Alzheimer disease and vascular dementia.

16 lts were similar for Alzheimer's disease and vascular dementia.

17 g speed and more than quadrupled the risk of vascular dementia.

18 to increased risk of Alzheimer's disease and vascular dementia.

19 attributed primarily to Alzheimer disease or vascular dementia.

20 role of inflammatory cells in the genesis of vascular dementia.

21 which was similar for Alzheimer disease and vascular dementia.

22 .5%) had Alzheimer disease and 95 (8.1%) had vascular dementia.

23 sease dementia, frontotemporal dementia, and vascular dementia.

24 d in Alzheimer's disease and even more so in vascular dementia.

25 isease, there are no licensed treatments for vascular dementia.

26 e but only slightly and not significantly in vascular dementia.

27 y represent a novel therapeutic strategy for vascular dementia.

28 beta1-42 in Parkinson's disease dementia and vascular dementia.

29 zheimer's disease and vascular dementia, and vascular dementia.

30 erebral perfusion in Alzheimer's disease and vascular dementia.

31 rmal regulation of white matter perfusion in vascular dementia.

32 ery occlusion (BCCAO) was used as a model of vascular dementia.

33 es in subjects with post-stroke dementia and vascular dementia.

34 ementia), with most cases being diagnosed as vascular dementia.

35 tive dysfunction in post-stroke dementia and vascular dementia.

36 successful against the progressive nature of vascular dementia.

37 tral nervous system injury in a rat model of vascular dementia.

38 d sequelae ranging from cognitive sparing to vascular dementia.

39 tly in patients with Alzheimer's disease and vascular dementia.

40 a leading cause of cognitive impairment and vascular dementia.

41 over 2 years in both Alzheimer's disease and vascular dementia.

42 troke survivors met the current criteria for vascular dementia.

43 ascular dementia) and sub-cortical ischaemic vascular dementia.

44 RNA to be markedly elevated in AD but not in vascular dementia.

45 also significantly elevated in AD but not in vascular dementia.

46 s blood brain barrier (BBB) permeability and vascular dementia.

47 A(A)) agonist, mitigates the AD syndrome and vascular dementia.

48 to support widespread use of these drugs in vascular dementia.

49 y contribute to early cognitive decline and (vascular) dementia.

50 1 [5]), 30 were patients diagnosed as having vascular dementia (37% female, mean [SD], 76 [9]; Mini-M

51 entia (HR, 2.0; 95% CI, 1.2-3.4), especially vascular dementia (4.3; 1.1-17.0), but not Alzheimer dis

52 oradic Alzheimer's disease, 81 patients with vascular dementia, 61 stroke patients without dementia,

53 ssigned to one cluster and the patients with vascular dementia (91%), frontotemporal dementia (94%),

54 Vascular dementia accounts for approximately 15-20% of a

55 Alzheimer's disease accounts for 60% whereas vascular dementia accounts for approximately 30% of the

56 wever, MI was associated with higher risk of vascular dementia (aHR, 1.35; 95% CI, 1.28-1.43), which

57 The efficacy of memantine in vascular dementia also requires further investigation.

58 fectiveness of memantine in the treatment of vascular dementia, although it has not been approved for

59 n-Alzheimer's dementia (47 of which involved vascular dementia and 8 of which involved other types of

60 post-mortem tissue from Alzheimer's disease, vascular dementia and age-matched control brains.

61 ; the heterozygous live normally but develop vascular dementia and Alzheimer's disease (AD) in later

62 ential role for anti-inflammatory therapy in vascular dementia and Alzheimer's disease, and perhaps e

63 tHcy) is a strong modifiable risk factor for vascular dementia and Alzheimer's disease.

64 rug therapy, and the combination of keywords vascular dementia and drug therapy.

65 ntegrity and have been recently discussed in vascular dementia and neuroinflammatory disorders.

66 ls of two serotonin receptors in subtypes of vascular dementia and relate any changes to cognition.

67 r the apolipoprotein E polymorphism, and the vascular dementia and stroke groups were typed at the HL

68 various neuropathologic disorders including vascular dementia and stroke.

69 lateral prefrontal cortex of post-stroke and vascular dementia and, of mixed and Alzheimer's disease

70 e artery territory infarction (multi-infarct vascular dementia) and sub-cortical ischaemic vascular d

71 eveloped Alzheimer disease, 64 men developed vascular dementia, and 250 men developed all-cause demen

72 was 9% (2.8% for Alzheimer disease, 1.6% for vascular dementia, and 4.5% for other dementias).

73 (65%) had Alzheimer's disease, 62 (19%) had vascular dementia, and 53 (16%) had another DSM-IV demen

74 to have neuroprotective effects on ischemic, vascular dementia, and amyloid-beta (Abeta)-infused anim

75 ortex of brain tissue from patients with AD, vascular dementia, and controls.

76 T allele significantly increases the risk of vascular dementia, and increases the risk of Alzheimer's

77 mer's disease, mixed Alzheimer's disease and vascular dementia, and vascular dementia.

78 Prevalence of vascular dementia appears to be slightly lower than in J

79 Intracerebral hemorrhagic stroke and vascular dementia are age- and hypertension-associated m

80 Stroke and vascular dementia are leading causes of morbidity and mo

81 al substrates associated with post-stroke or vascular dementia are poorly understood, particularly th

82 arcts and leukoencephalopathy (CADASIL) is a vascular dementia arising from abnormal arteriolar vascu

83 tterns were found with Alzheimer disease and vascular dementia as outcomes.

84 imer's disease, dementia with Lewy bodies or vascular dementia at presentation.

85 oreactivity was increased in post-stroke and vascular dementia compared with post-stroke patients wit

86 memory abilities and morphology in rats with vascular dementia compared with rats with untreated vasc

87 Trials were of 6-month duration with similar vascular dementia criteria and outcome measures.

88 patients have reported that individuals with vascular dementia do better on memory tests and worse on

89 51 (95% CI 1.49-4.21) for the development of vascular dementia for individuals with a CT or TT genoty

90 evelopment of dementia (eg, senile dementia, vascular dementia, frontotemporal dementia, and Alzheime

91 In the vascular dementia, frontotemporal dementia, dementia wit

92 e distribution of TNF-alpha genotypes in the vascular dementia group differed significantly from that

93 prevalence rates of Alzheimer's disease and vascular dementia have differed.

94 es of abnormal gait, unsteady gait predicted vascular dementia (hazard ratio, 2.61), as did frontal g

95 , abnormal gait predicted the development of vascular dementia (hazard ratio, 3.46 [95 percent confid

96 = 1.11 [1.03-1.19], p = 0.0044) and mixed or vascular dementia (HR = 1.21 [1.04-1.41], p = 0.0163).

97 ubjects (Alzheimer's disease in 61 subjects, vascular dementia in 30, mixed dementia in 25, and other

98 dementias, including Alzheimer's disease and vascular dementia in elderly people.

99 e NOTCH3 gene trigger adult-onset stroke and vascular dementia in patients with CADASIL (cerebral aut

100 ubtypes (Alzheimer disease [AD] and mixed or vascular dementia) in older community-dwelling persons.

101 ) compared with control subjects, but not in vascular dementia, in which endothelin 1 tended to be el

102 and dementia (probable Alzheimer disease and vascular dementia, including possible Alzheimer disease

103 ith Alzheimer disease or other dementia like vascular dementia, indicative that these antibodies hold

104 Vascular dementia is caused by different cerebrovascular

105 Vascular dementia is now recognized as the second most c

106 Vascular dementia is one of the most common causes of de

107 essel disease leading to ischemic stroke and vascular dementia is the neurodegenerative syndrome cere

108 Next to Alzheimer disease, vascular dementia is the second most common form of deme

109 Vascular dementia is the second most common type of deme

110 In Parkinson's disease dementia and vascular dementia low cerebrospinal fluid amyloid-beta1-

111 Vascular dementia may respond, at least to some extent,

112 ct vascular dementia, sub-cortical ischaemic vascular dementia, mixed Alzheimer's disease/vascular de

113 ognitive disorders, including the hereditary vascular dementias, multi-infarct dementia, post-stroke

114 tem cohorts of Alzheimer's disease (n = 49), vascular dementia (n = 17) and control brains (n = 33) f

115 Alzheimer disease (n = 154) and vascular dementia (n = 36) were the 2 most frequent diag

116 ts with dementia (Alzheimer's disease, N=84; vascular dementia, N=60).

117 ation in the brain of diabetic patients with vascular dementia or Alzheimer disease (AD), nondiabetic

118 cortex of patients with either multi-infarct vascular dementia or SND, compared to age-matched contro

119 vascular dementia, mixed Alzheimer's disease/vascular dementia or stroke no dementia (SND).

120 r dementia compared with rats with untreated vascular dementia (P < .05).

121 nificantly less in AD compared with ischemic vascular dementia (p < 0.02), but there was no significa

122 tive disorders, such as Alzheimer's disease, vascular dementia, Parkinson's disease, and Huntington's

123 onal decline in both Alzheimer's disease and vascular dementia patients over a 2-year period.

124 ) Alzheimer's disease patients, and 27 (45%) vascular dementia patients.

125 novel therapies for stroke and multi-infarct vascular dementia patients.

126 ease (primary or contributing), and 4.2% for vascular dementia (primary or contributing).

127 The Alzheimer disease/vascular dementia ratio was 1.5 for cases attributed pri

128 re consistently observed in AD than ischemic vascular dementia, severity of loss shows the expected c

129 sporadic form of Alzheimer disease (AD) and vascular dementia share many risk factors, and their pat

130 The current narrow definitions of vascular dementia should be broadened to recognise the i

131 between the neurochemistry of multi-infarct vascular dementia/SND and sub-cortical ischaemic vascula

132 associated with lower CSF Abeta42 in AD and vascular dementia (standardized beta = -0.09, P = .003;

133 42 in control participants and patients with vascular dementia (standardized beta = -0.18, P = .002;

134 acunes was associated with higher Abeta42 in vascular dementia (standardized beta = 0.17, P = .07) an

135 rtices of patients with either multi-infarct vascular dementia, sub-cortical ischaemic vascular demen

136 s examining the neurochemistry of individual vascular dementia subtypes.

137 ular dementia/SND and sub-cortical ischaemic vascular dementia, suggesting that pharmacological manip

138 loid PET analysis, especially in subcortical vascular dementia (SVaD) patients.

139 MI was associated with higher risk of vascular dementia throughout follow-up, and this associa

140 xpression in post-mortem brain tissue in AD, vascular dementia (VaD) and controls.

141 ls were measured in 20 AD, 20 control and 15 Vascular dementia (VaD) brains by real-time PCR (RT-PCR)

142 cidence of dementia, Alzheimer disease (AD), vascular dementia (VaD), and CIND by age.

143 he coexistence of Alzheimer disease (AD) and vascular dementia (VaD), is likely to increase as the po

144 model of chronic cerebral hypoperfusion and vascular dementia (VaD).

145 gnoses of Alzheimer disease (AD), and 35% of vascular dementia (VaD).

146 Alzheimer's disease (AD; 1.8 [1.1-2.9]), and vascular dementia (VsD; 2.3 [1.1-5.0]).

147 the pathogenesis of Alzheimer's disease and vascular dementia, we did an epidemiological study of th

148 Prevalence levels for Alzheimer disease and vascular dementia were also estimated.

149 rates of dementia, Alzheimer's disease, and vascular dementia were examined in the Japanese American

150 Diagnoses of Alzheimer disease and vascular dementia were secondary outcome measures.

151 e patients with cerebral ischemic stroke and vascular dementia, which significantly increase the risk

152 eeded to identify subgroups of patients with vascular dementia who might benefit.